Mustang Bio (MBIO): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The GURU.Markets price chart for Mustang Bio, Inc. (MBIO), a company operating in the genetic technology sector, shows an EV/EBITDA ratio of 0.00. The current share price already prices in the liquidity shortage, while CAR-T drug trials are driving growth. A proprietary facility in Massachusetts ensures production stability, as management prioritizes the most effective methods for combating oncology and hereditary pathologies.
mustangbio.com (MBIO) - metric breakdowns and financial figures
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
- financial results and valuation multiples details:
MBIO - Net Financial Result|Expected Profit Mustang Bio, Inc.|MBIO - Price to Earnings Multiple|Forward P/E Multiple Mustang Bio|MBIO - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio MBIO|MBIO - Operating income before deduction of amortization|Earnings per share for the last twelve months Mustang Bio|MBIO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth mustangbio.com|MBIO - Earnings per share growth in current year|Earnings growth forecast for next year Mustang Bio, Inc.
Comprehensive company analysis:MBIO (Mustang Bio Corp)
For biotech sector investors, this indicator serves as a tool to assess the valuation of Mustang Bio, Inc. (MBIO) while accounting for debt load and operational efficiency. By analyzing the EV/EBITDA trend of this capital-intensive company—calculated as the ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization—one can determine how effectively management is investing resources into priority cell therapy programs.
Competitor analysis
EV/EBITDA Multiple TEM (tempus.com)|EV/EBITDA Multiple Qiagen Corp QGEN|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN (repligen.com) - Enterprise Value to Operating Income Before Depreciation|RNA: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple CRISPR Therapeutics Inc CRSP|Enterprise Value to EBITDA Ratio WGS|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SRPT (sarepta.com)|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics Inc (TXG)|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Stoke Corp|BLFS (BioLife Solutions, Inc.) - Enterprise Value to EBITDA Ratio|wavelifesciences.com - Business Value to Operating Income Before Depreciation|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Sionna Therapeutics, Inc. (SION) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|Taysha Corp - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple QURE (uniQure N.V.)|MGTX - Enterprise Value to EBITDA Ratio|RGNX: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Solid Biosciences Inc SLDB|Ocugen Corp (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio PacBio Corp|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DSGN|EV/EBITDA Multiple RCKT|Total Company Value to Operating Income Before Depreciation Ratio 4DMT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. (KRRO) - Company Value to EBITDA|Editas Medicine, Inc. - EV/EBITDA Multiple|SLN (silence-therapeutics.com) - Enterprise Value to Operating Income Before Depreciation|proqr.com (PRQR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CDXS|SGMO (Sangamo) - EV/EBITDA Multiple|EV/EBITDA Multiple Nautilus Biotechnology Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|Enterprise Value to EBITDA Ratio precisionbiosciences.com DTIL|Generation Bio - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Boundless Bio Inc. BOLD|XCUR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Imunon, Inc. IMNN|PHIO (phiopharma.com) - Enterprise Value to EBITDA Ratio|RNAZ: Enterprise Value to Operating Income Before Depreciation Ratio|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Sciences Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|immunoprecise.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMGA (Omega Therapeutics)|Enterprise Value to EBITDA Multiple singulargenomics.com|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals Inc.)|TBIO: EV/EBITDA Multiple|TCON (TRACON Pharmaceuticals, Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UBX (Unity Biotechnology) - EV/EBITDA Multiple
